Apimeds Pharmaceutical U.S, Inc. 宣布,公司不认可通过股东同意书程序单方面推选的赵英植(Youngjik Cho)担任董事的任命。该任命程序未遵循公司章程规定的正式流程,公司管理层认为此次人事变动缺乏法律效力。董事会将依法采取必要措施维护公司治理结构的稳定性。
Apimeds Pharmaceutical U.S, Inc. 宣布,公司不认可通过股东同意书程序单方面推选的赵英植(Youngjik Cho)担任董事的任命。该任命程序未遵循公司章程规定的正式流程,公司管理层认为此次人事变动缺乏法律效力。董事会将依法采取必要措施维护公司治理结构的稳定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.